Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Non-cash Items (2021 - 2024)

Historic Non-cash Items for Lyra Therapeutics (LYRA) over the last 4 years, with Q4 2024 value amounting to $2.8 million.

  • Lyra Therapeutics' Non-cash Items fell 5544.4% to $2.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $2.8 million, marking a year-over-year decrease of 5544.4%. This contributed to the annual value of $2.8 million for FY2024, which is 5897.66% up from last year.
  • Latest data reveals that Lyra Therapeutics reported Non-cash Items of $2.8 million as of Q4 2024, which was down 5544.4% from $1.3 million recorded in Q3 2024.
  • In the past 5 years, Lyra Therapeutics' Non-cash Items ranged from a high of $12.9 million in Q1 2024 and a low of $57000.0 during Q1 2023
  • For the 4-year period, Lyra Therapeutics' Non-cash Items averaged around $2.7 million, with its median value being $1.3 million (2022).
  • In the last 5 years, Lyra Therapeutics' Non-cash Items plummeted by 9254.9% in 2023 and then soared by 2248070.18% in 2024.
  • Quarter analysis of 4 years shows Lyra Therapeutics' Non-cash Items stood at $918000.0 in 2021, then crashed by 58.82% to $378000.0 in 2022, then soared by 1575.66% to $6.3 million in 2023, then tumbled by 55.44% to $2.8 million in 2024.
  • Its last three reported values are $2.8 million in Q4 2024, $1.3 million for Q3 2024, and $1.4 million during Q2 2024.